Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02767531 · ClinicalTrials.gov registry record · Phase 2
Orlistat for the Treatment of Type I Hyperlipoproteinemia
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT02767531 is a Phase 2 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 2 participants.
The verdict
NCT02767531, a Phase 2 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Patients with Type I Hyperlipoproteinemia (T1HLP) have a rare form of hypertriglyceridemia marked by significant chylomicronemia and recurrent episodes of acute pancreatitis. T1HLP is caused by a deficiency of lipoprotein lipase or one of its cofactors. Many patients are a challenge to treat, as the only effective therapy available is an extremely low fat diet. This diet is exceedingly difficult to follow, and despite adherence, many patients still have chylomicronemia and develop acute pancreatitis. Specific Aim: To determine the efficacy of a gastric and pancreatic lipase inhibitor, Orlistat, in reducing serum triglyceride levels in patients with T1HLP.
Interventions
- DRUG Orlistat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-12 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02767531
The ClinicalTrials.gov registry entry for NCT02767531 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Orlistat is the first listed.
NCT02767531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02767531 about?
NCT02767531 is a clinical study titled "Orlistat for the Treatment of Type I Hyperlipoproteinemia". Patients with Type I Hyperlipoproteinemia (T1HLP) have a rare form of hypertriglyceridemia marked by significant chylomicronemia and recurrent episodes of acute pancreatitis. T1HLP is caused by a deficiency of lipoprotein lipase or one of its cofactors. Many patients are a challenge to treat, as the...
What is the current status of trial NCT02767531?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2015-12. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT02767531?
The interventions under investigation include: Orlistat (DRUG).
Who is sponsoring clinical trial NCT02767531?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.